Compare · MDLN vs NVCR
MDLN vs NVCR
Side-by-side comparison of Medline Inc. (MDLN) and NovoCure Limited (NVCR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDLN and NVCR operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $47.31B, about 23.7x NVCR ($2.00B).
- Over the past year, MDLN is down 11.6% and NVCR is down 6.1% - NVCR leads by 5.5 points.
- MDLN has been more active in the news (21 items in the past 4 weeks vs 18 for NVCR).
- Both have 25 recent analyst ratings on file.
- Company
- Medline Inc.
- NovoCure Limited
- Price
- $36.01+6.54%
- $17.26+2.49%
- Market cap
- $47.31B
- $2.00B
- 1M return
- -8.80%
- -3.47%
- 1Y return
- -11.64%
- -6.14%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- 2015
- News (4w)
- 21
- 18
- Recent ratings
- 25
- 25
NovoCure Limited
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The company markets Optune and Optune Lua, a Tumor Treating Fields delivery system for use as a monotherapy treatment for adult patients with glioblastoma. It is also developing products for brain metastases, non-small cell lung cancer, pancreatic cancer, gastric cancer, ovarian cancer, liver cancer, and mesothelioma. The company markets its products in the European Union, Japan, and internationally. It has a clinical trial collaboration agreement with MSD to evaluate tumor treating fields together with KEYTRUDA, an anti-PD-1 therapy; and a strategic alliance with the NYU Grossman School of Medicine's Department of Radiation Oncology that provides a framework for preclinical and clinical development projects studying Tumor Treating Fields. NovoCure Limited was founded in 2000 and is based in Saint Helier, Jersey.
Latest MDLN
- Principal Accounting Officer Corcoran Jessi L bought $170,750 worth of shares (5,000 units at $34.15) (SEC Form 4)
- Medline Inc. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Entry into a Material Definitive Agreement
- Large owner Hellman & Friedman Capital Partners X (Parallel), L.P. sold $1,164,385,709 worth of shares (31,868,237 units at $36.54) and disposed of 1,887,801 shares (SEC Form 4)
- Director Healy Patrick J acquired 202,106 shares, increasing direct ownership by 15% to 1,387,921 units (SEC Form 4)
- Large owner Bx Mozart Ml-2 Holdco L.P. sold $1,217,349,994 worth of shares (33,317,824 units at $36.54) and disposed of 438,214 shares (SEC Form 4)
- Large owner Bcp 8 Holdings Mozart Manager L.L.C. sold $1,217,349,994 worth of shares (33,317,824 units at $36.54) and disposed of 438,214 shares (SEC Form 4)
- Medline's Prime Vendor model expands outside the United States
- Medline Inc. announces closing of upsized secondary offering of Class A common stock
- Medline announces participation in upcoming investor conferences
- MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update
Latest NVCR
- NovoCure Limited filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Director Stafford Kristin was granted 11,610 units of Ordinary Shares, increasing direct ownership by 103% to 22,934 units (SEC Form 4)
- Chief Executive Officer Leonard Frank X sold $614,635 worth of Ordinary Shares (34,273 units at $17.93), decreasing direct ownership by 7% to 459,520 units (SEC Form 4) (withholding tax)
- Director Leung Gabriel was granted 11,610 units of Ordinary Shares, increasing direct ownership by 13% to 101,109 units (SEC Form 4)
- Director Ocean Allyson J was granted 11,610 units of Ordinary Shares, increasing direct ownership by 103% to 22,934 units (SEC Form 4)
- Director Scannell Timothy J was granted 11,610 units of Ordinary Shares, increasing direct ownership by 81% to 25,898 units (SEC Form 4)
- Director Hilleman Jeryl L was granted 11,610 units of Ordinary Shares, increasing direct ownership by 84% to 25,471 units (SEC Form 4)
- Director Hung David was granted 11,610 units of Ordinary Shares, increasing direct ownership by 57% to 32,075 units (SEC Form 4)
- Director Madden Martin J. was granted 11,610 units of Ordinary Shares, increasing direct ownership by 62% to 30,284 units (SEC Form 4)
- Director Vernon W Anthony was granted 11,610 units of Ordinary Shares, increasing direct ownership by 6% to 209,267 units (SEC Form 4)